Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACNU + vincristine is a chemotherapy combination used primarily for treating certain types of cancer, particularly anaplastic carcinoma of the lung. This combination therapy was designed to address the heterogeneous nature of anaplastic carcinoma, which can include undifferentiated squamous cell carcinoma, adenocarcinoma, large cell carcinoma, and small cell carcinoma. ACNU (nimustine) is a nitrosourea compound that acts as an alkylating agent, cross-linking DNA and inhibiting cancer cell growth. Vincristine is a vinca alkaloid that binds to tubulin, preventing microtubule formation during cell division, thus stopping cancer cells from dividing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ACNU + vincristine.